“The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period” says new Visiongain report

06 March 2020
Pharma

Visiongain has launched a new pharma report Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.

The gene therapy market is in early stages of its development, this new Visiongain report analyses the emerging gene therapy market, a field holding great technological and commercial potential. Gene therapy is no longer a treatment solely for rare diseases but has expanded its targets and can now be applied to cancer, cardiovascular diseases, diabetes and more. We have already seen gene therapies launched in recent years and are likely to see upcoming launches due to rapid advancement and the number of clinical trials in this field. Gene therapy has seen many advances in recent years, particularly with vector technology, with AAV and lentiviral vectors showing much potential.

The lead analyst of the report commented "The growth of the overall gene therapy market will be primarily driven by growth in the cardiovascular and rare diseases sector. Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets. The market still faces substantial challenges related to ethics, pricing and scalability. Companies looking to market their products optimally should also be developing companion diagnostics for predictive biomarker testing, to market alongside their gene therapies. These companies will also need to agree on creating reimbursements models that will convince health care providers to invest in these novel therapies."

Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Pfizer, Novartis & GSK.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2022-2032

The desire for various types of medications to assist combat a growing number of chronic diseases & lifestyle-related ailments is fuelling the overall deep freeze packaging logistics market demand.

14 January 2022

Read

Visiongain Publishes Pre-Filled Syringes Market Report 2022-2032

With COVID-19 pandemic, the prefilled syringes business has witnessed a significant growth. Since the outbreak of the pandemic, global market players involved in the development of the prefilled syringes market across the globe have increased their investment in raw materials and resources owing to the rise in demand for home based healthcare services.

11 January 2022

Read

Visiongain Publishes Single-use Bioprocessing Probes & Sensors Market Report 2022-2032

To promote their organic revenue growth and market presence, the top companies are pursuing different strategic initiatives such as OEM collaborations and new product development with better technological intricacy.

05 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever